A Phase 1, Open-Label, Dose-Escalation Study of the Safety and Efficacy of an AntiCD38 Antibody Drug Conjugate (STI-6129) in Patients with Relapsed or Refractory Systemic AL Amyloidosis
Study of STI-6129 in Patients with Relapsed or Refractory Systemic AL Amyloidosis
Sponsor: Sorrento Therapeutics, Inc.
Enrolling: Male and Female Patients
IRB Number: AAAT1237
U.S. Govt. ID: NCT04316442
Contact: Research Nurse Navigator: 212-342-5162 / cancerclinicaltrials@cumc.columbia.edu
Additional Study Information: The purpose of this study is to evaluate the safety and effectiveness of an antibody drug (STI-6129) in patients with AL amyloidosis that has returned or has not responded to treatment (relapsed/refractory). The study drug (STI-6129) will be given in 3 injections through a needle, into a vein as an intravenous (IV), with 21 days between each injection.
This study is closed
Investigator
Suzanne Lentzsch, MD
Do You Qualify?
Are you 18 years of age or older? Yes No
Do you have AL amyloidosis? Yes No
Has your disease returned or has not responded to treatment? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder



Cancel
For more information, please contact:
Research Nurse Navigator
cancerclinicaltrials@cumc.columbia.edu
212-342-5162
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE